Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell–mediated remissions
- 9 October 2018
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (19) , 2568-2580
Abstract
Conventional local tumor irradiation (LTI), delivered in small daily doses over several weeks, is used clinically as a palliative, rather than curative, treatment for chemotherapy-resistant diffuse large B-cell lymphoma (DLBCL) for patients who are ineligible for hematopoietic cell transplantation. Our goal was to test the hypothesis that accelerated, but not conventional, LTI would be more curative by inducing T cell–mediated durable remissions. We irradiated subcutaneous A20 and BL3750 lymphoma tumors in mice with a clinically relevant total radiation dose of 30 Gy LTI, delivered in 10 doses of 3 Gy over 4 days (accelerated irradiation) or as 10 doses of 3 Gy over 12 days (conventional irradiation). Compared with conventional LTI, accelerated LTI resulted in more complete and durable tumor remissions. The majority of these mice were resistant to rechallenge with lymphoma cells, demonstrating the induction of memory antitumor immunity. The increased efficacy of accelerated LTI correlated with higher levels of tumor cell necrosis vs apoptosis and expression of “immunogenic cell death” markers, including calreticulin, heat shock protein 70 (Hsp70), and Hsp90. Accelerated LTI–induced remissions were not seen in immunodeficient Rag-2−/− mice, CD8+ T-cell–depleted mice, or Batf-3−/− mice lacking CD8α+ and CD103+ dendritic cells. Accelerated, but not conventional, LTI in immunocompetent hosts induced marked increases in tumor-infiltrating CD4+ and CD8+ T cells and MHCII+CD103+CD11c+ dendritic cells and corresponding reductions in exhausted PD-1+Eomes+CD8+ T cells and CD4+CD25+FOXP3+ regulatory T cells. These findings raise the possibility that accelerated LTI can provide effective immune control of human DLBCL. Key Points Accelerated radiotherapy of B-cell lymphoma enhances immunogenic cell death and antitumor immunity compared with conventional radiotherapy. CD8+ T cells and CD8+ cross-priming dendritic cells are required for this radiation-induced antitumor immunity. Visual AbstractKeywords
This publication has 39 references indexed in Scilit:
- Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology GroupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2018
- Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axesOncotarget, 2016
- Radiotherapy and Immunogenic Cell DeathSeminars in Radiation Oncology, 2015
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell ImmunityCancer Cell, 2014
- Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell linesRadiation Oncology, 2014
- Progenitor and Terminal Subsets of CD8 + T Cells Cooperate to Contain Chronic Viral InfectionScience, 2012
- Immunogenic cell death and DAMPs in cancer therapyNature Reviews Cancer, 2012
- Apoptosis and Beyond: Cytometry in Studies of Programmed Cell Death2011
- Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in miceJournal of Clinical Investigation, 2010
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007